Livzon Pharmaceutical Group (HK:1513) has released an update.
Livzon Pharmaceutical Group has entered into a 2025 Continuing Guarantee Support Framework Agreement with Livzon MAB, agreeing to provide guarantees up to RMB 2.1 billion to support Livzon MAB’s credit facilities from 2025 to 2027. This arrangement is classified as a discloseable and continuing connected transaction under the Hong Kong Listing Rules and requires approval from independent shareholders. Additionally, an Extraordinary General Meeting (EGM) will be convened for shareholder approval, with Frontpage Capital appointed as the independent financial adviser.
For further insights into HK:1513 stock, check out TipRanks’ Stock Analysis page.
